Retham Technologies

Biotechnology ResearchWisconsin, United States2-10 Employees

Retham Technologies LLC is a small biotechnology research company based in Milwaukee, Wisconsin, founded in 2017. It is developing HITDx, an in vitro diagnostic assay intended for early and more accurate diagnosis of heparin-induced thrombocytopenia at or near the point of care. Heparin-induced thrombocytopenia is a serious adverse reaction to heparin that can cause low platelets and, in a subset of cases, thrombosis with potentially life-threatening outcomes; current hospital testing relies on PF4 ELISAs that have high false-positive rates, while the serotonin release assay is limited by availability and complexity.

The primary customers are hospitals and clinical laboratories that perform HIT testing, with the aim of enabling timely and appropriate therapy and reducing exposure to non-heparin anticoagulants prompted by false positives. HITDx seeks to improve diagnostic speed and accuracy within HIT management, addressing shortcomings in current testing workflows. Operating in the biotechnology research space, the company concentrates on translating scientific findings into practical diagnostic tools for adverse drug reactions.

Sign up for free to view info

Email Format Employee directory